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Abstract 18 
This phase II, randomized, double-blind study evaluated the immune responses elicited 19 
by RTS,S vaccines containing adjuvant system AS01 or AS02 as compared to non-20 
adjuvanted RTS,S in healthy, malaria-naïve adults (ClinicalTrials.gov identifier: 21 
NCT00443131). Thirty-six subjects were randomized (1:1:1) to receive RTS,S/AS01, 22 
RTS,S/AS02, or RTS,S/saline (control) at months 0, 1, and 2. Antibody responses to 23 
Plasmodium falciparum circumsporozoite (CS) and hepatitis B surface (HBs) antigens 24 
were assessed and cell-mediated immune (CMI) responses evaluated by flow cytometry 25 
using intracellular cytokine staining on peripheral blood mononuclear cells. Anti-CS 26 
antibody avidity was also characterized. Safety and reactogenicity after each vaccine 27 
dose were monitored. One month after the third vaccine dose, RTS,S/AS01 and 28 
RTS,S/AS02 recipients had significantly higher anti-CS antibody geometric mean titers 29 
(GMTs) than recipients of non-adjuvanted RTS,S (p<0.0001 and p=0.0011, 30 
respectively). The anti-CS antibody GMT was significantly higher with RTS,S/AS01 than 31 
with RTS,S/AS02 (p=0.0135). Anti-CS antibody avidity was in the same range in all 32 
groups. CMI responses (CS- and HBs-specific CD4+ T cell responses) were greater for 33 
both RTS,S/AS groups than for the non-adjuvanted RTS,S control group. Reactogenicity 34 
was in general higher in the RTS,S/AS groups than in the control group. Most grade 3 35 
solicited adverse events (AEs) were of short duration and grade 3 solicited general AEs 36 
were infrequent in the three groups. No serious adverse events were reported. In 37 
conclusion, in comparison with non-adjuvanted RTS,S, both RTS,S/AS vaccines 38 
exhibited better CS-specific immune responses. The anti-CS antibody response was 39 
significantly higher with RTS,S/AS01 than with RTS,S/AS02. The adjuvanted vaccines 40 
had acceptable safety profiles. 41 
Keywords: adjuvant, AS01, AS02, vaccine, malaria, cell-mediated immunity, humoral 42 
immunity  43 
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Introduction 44 
The RTS,S/AS candidate malaria vaccine is under clinical development for possible use 45 
in the Expanded Program on Immunization for infants and children in sub-Saharan Africa 46 
as an addition to existing preventive and treatment measures, such as insecticide-47 
treated bed nets, indoor residual spraying, and intermittent preventive treatment with 48 
sulfadoxine-pyrimethamine.1,2 The antigen component of the candidate malaria vaccine, 49 
RTS,S, consists of repeat sequences of the Plasmodium falciparum circumsporozoite 50 
(CS) protein fused to the hepatitis B surface antigen (HBs).3 Two adjuvant systems have 51 
been evaluated with the RTS,S antigen: AS02, which consists of an oil-in-water 52 
emulsion with monophosphoryl lipid A (MPL) and Quillaja saponaria Molina, fraction 21 53 
(QS21, Antigenics Inc., a wholly owned subsidiary of Agenus Inc., Lexington, MA, USA), 54 
as immunostimulants, and AS01, a related liposome-based adjuvant system that also 55 
contains MPL and QS21.3,4  56 
Anti-CS antibody titers and, to a lesser extent, CS-specific CD4+ T cells elicited by 57 
RTS,S have been identified as immunological markers associated with protection.5-7 CS-58 
specific CD4+ T cells induced by RTS,S produce a mixture of cytokines, such as 59 
interleukin (IL)-2, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ.7-11 In phase 2 60 
clinical trials of adults and children, the RTS,S/AS01 formulation had an improved 61 
immunogenicity profile, in terms of humoral and cell-mediated immune (CMI) responses, 62 
and an equally favorable safety profile as compared with RTS,S/AS02.11-14 The 63 
RTS,S/AS01 formulation was consequently selected for phase 3 development. First 64 
results from the ongoing phase 3 trial in Africa show the vaccine candidate provides 65 
significant protection against clinical and severe malaria in young children and 66 
infants.15,16 67 
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The Committee for Medicinal Products for Human Use (CHMP) of the European 68 
Medicines Agency (EMA) recommended to establish in small studies the effect of 69 
vaccine adjuvants on immune responses to the antigens with which they are 70 
combined.17 The present study was therefore designed to evaluate the humoral and CMI 71 
responses elicited by RTS,S/AS01 and RTS,S/AS02 as compared to non-adjuvanted 72 
RTS,S antigen. The study also evaluated antibody avidity against the CS repeat antigen. 73 
This trial was conducted in healthy, malaria-naïve adults in order to control for factors 74 
associated with immune responses following malaria exposure. As subjects with pre-75 
existing anti-HBs immunity may have improved immune responses against both HBs 76 
and CS when compared to HBs-naïve subjects,14 for uniformity, only adults 77 
seroprotected for HBs at baseline were enrolled in the trial.  78 
Results 79 
Study population 80 
A total of 56 malaria-naïve volunteers were screened of which 36 were randomized 81 
(1:1:1) to the vaccination groups (Fig. 1); all participants completed the study. Two were 82 
excluded from the according-to-protocol (ATP) cohort for immunogenicity because of 83 
incomplete vaccination. The demographic profile of participants was balanced across 84 
groups (Table 1). All participants were white (Caucasian/European heritage). 85 
Immunogenicity 86 
Humoral responses 87 
Antibodies to CS were determined by evaluating immunoglobulin G (IgG) responses to 88 
the CS-repeat region using a standard enzyme-linked immunosorbent assay (ELISA). 89 
The antibody response was evaluated in the ATP cohort for immunogenicity. Before 90 
vaccination, none of the subjects had detectable anti-CS antibody responses (Table 2). 91 
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One month after each dose, all vaccine recipients in each group were seropositive for 92 
anti-CS antibodies (≥0.5 EU/mL), apart from one participant in the RTS,S/saline group 93 
who was seronegative after the third vaccine dose.  94 
One month after the third vaccine dose, anti-CS antibody geometric mean titers (GMTs) 95 
were significantly higher in the RTS,S/AS01 and RTS,S/AS02 groups than in the 96 
RTS,S/saline group (p<0.0001, RTS,S/AS01 versus RTS,S/saline; p=0.0011, 97 
RTS,S/AS02 versus RTS,S/saline) (Table 3). Anti-CS GMTs were 13-fold and 6-fold 98 
higher for recipients of RTS,S/AS01 and RTS,S/AS02, respectively, than for recipients of 99 
RTS,S/saline. In the adjuvanted RTS,S groups, GMTs increased with subsequent doses 100 
(Table 2) and significantly higher responses (p=0.0135) were observed with 101 
RTS,S/AS01 than with RTS,S/AS02 (Table 3). 102 
Anti-CS antibody avidity (as determined by ELISA using the chaotropic agent, 103 
ammonium thiocyanate, and expressed as the avidity index) was in the same range for 104 
the three groups at each time point (Fig. 2).  105 
All participants had seroprotective anti-HBs antibody titers (≥10 mIU/mL) before 106 
vaccination, and anti-HBs antibody GMTs increased after the first dose of RTS,S (range: 107 
356888–536123 mIU/mL), but did not increase further with subsequent doses (Table 2). 108 
Cell-mediated immunity 109 
CMI responses to the CS and HBs antigens were assessed by flow cytometry using 110 
intracellular cytokine staining (ICS) analyses. Following vaccination, CS-specific CD4+ T 111 
cell responses, defined as CD4+ cells expressing at least two of the immune markers 112 
CD40L, IL-2, TNF-α, and/or IFN-γ, were detected in all vaccine groups with a trend for 113 
higher responses in the adjuvanted RTS,S groups over the RTS,S/saline group (Fig. 114 
3A).  115 
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As expected from the primed status of the participants in terms of anti-HBs antibody 116 
titers, CD4+ T cell frequencies are much higher following stimulation with HBs than with 117 
CS (Fig. 3B). HBs-specific CD4+ T cell responses were detected in all groups after 118 
vaccination, with a trend for higher median values in the adjuvanted RTS,S groups. 119 
Although some CD8+ T cell proliferation was observed following CS stimulation of 120 
peripheral blood mononuclear cells (PBMCs) harvested at screening, no vaccine-121 
induced CS- or HBs-specific CD8+ T cell responses were detected in any group (data 122 
not shown). 123 
Reactogenicity and safety 124 
Incidences of all solicited adverse events (AEs), apart from gastrointestinal symptoms, 125 
tended to be higher with the adjuvanted antigen than with unadjuvanted RTS,S (Fig. 4). 126 
There was no trend suggesting an increase in solicited AE incidence with subsequent 127 
vaccine doses (data not shown). Injection site pain was the most frequently reported 128 
solicited local AE in all vaccine groups (Fig. 4). All grade 3 local AEs resolved within the 129 
7-day follow up, except for two separate episodes of grade 3 redness after the first dose 130 
of RTS,S/AS01 that resolved on day 8 (participant received no further vaccine doses) 131 
and day 9, respectively. Fatigue and headache were the most frequently reported 132 
solicited general AEs (Fig. 4). Grade 3 solicited general AEs were infrequent and 133 
resolved within the 7-day follow-up, apart from one report of grade 3 gastrointestinal 134 
discomfort following the first dose of RTS,S/AS02, which resolved 14 days after 135 
vaccination; the participant received no further vaccine doses.  136 
At least one unsolicited AE was reported in 10 (83.3%) subjects in each of the RTS,S/AS 137 
groups and 6 (50.0%) subjects in the RTS,S/saline group. The incidence of unsolicited 138 
events reported by more than one subject in a single group is shown in Table 4; few 139 
were reported by more than two subjects. Unsolicited AEs that were considered to be 140 
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causally related to vaccination were reported by four recipients of RTS,S/AS01 (33.3%), 141 
five recipients of RTS,S/AS02 (41.7%), and three recipients of RTS,S/saline (25.0%). 142 
Each vaccine-related unsolicited AE occurred in one subject only for each group, except 143 
for injection site pruritus (reported in two subjects in the RTS,S/AS01 group), arthralgia 144 
(reported in two subjects in the RTS,S/AS01 group), and myalgia (reported in three 145 
subjects in the RTS,S/AS01 group). One related unsolicited AE had grade 3 intensity: 146 
myalgia, which followed the first dose of RTS,S/AS01 and resolved within 2 days. 147 
No serious AEs were reported during the study. No clinically relevant changes in clinical 148 
laboratory parameters were reported as AEs or serious AEs. 149 
Discussion 150 
The present study was designed to evaluate the humoral and cellular immune responses 151 
elicited by adjuvanted RTS,S as compared to non-adjuvanted RTS,S in healthy, malaria-152 
naïve adults. As priming with hepatitis B vaccine has been shown to influence immune 153 
responses against both CS and HBs,14 the immunological determinants contained in 154 
RTS,S, we enrolled subjects with detectable anti-HBs responses (≥10 mIU/ml) in an 155 
attempt to ensure baseline comparability. Adjuvantation was shown to strongly enhance 156 
immune responses, with RTS,S/AS01 and RTS,S/AS02 eliciting anti-CS antibody GMT 157 
responses that were 13- and 6-fold higher, respectively, than the response to non-158 
adjuvanted RTS,S. CS- and HBs-specific CD4+ T cell responses were also stronger with 159 
the adjuvanted RTS,S formulations as compared to RTS,S/saline, with a trend towards 160 
higher CMI responses in the RTS,S/AS01 group. Paradoxically one subject in the saline 161 
group showed a CS-specific  immune response after dose 1 which decreased over time 162 
and was undetectable at study end. We have no clear reason for this. However, 163 
although highly improbable, we can’t completely rule out the possibility that the subject 164 
erroneously received an adjuvanted vaccine at month 0.165 
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The results of this trial confirm those from a study of malaria-naïve adults conducted in 166 
the USA, which reported significantly greater CS-specific humoral immune responses 167 
and a tendency towards higher CD4+ T cell responses with RTS,S/AS01 than with 168 
RTS,S/AS02.11 In that study, vaccine efficacy against malaria challenge was 50% with 169 
RTS,S/AS01 and 32% with RTS,S/AS02, and significant correlations were found 170 
between protection against malaria challenge and both CS-specific antibody responses 171 
and CMI responses induced by the RTS,S vaccine.7,11 CD4+ T cells predominantly 172 
expressed CD40L, a co-stimulatory ligand required for T cell help that also induces the 173 
differentiation of B cells,18,19 and IL-2, a cytokine associated with memory T cells and T 174 
cell proliferation and differentiation.20 There was also a strong association between the 175 
frequency of IL-2 producing CD4+ T cells and titers of CS-specific antibodies in the same 176 
individual, suggesting that IL-2 may contribute to protection by promoting both cellular 177 
and humoral responses.7 Methods available at the time of the study, however, did not 178 
allow for a phenotypic analysis of the CS CD4+ T cell data. 179 
Induction of CD4+ T cells directed against P. falciparum CS protein by RTS,S adjuvanted 180 
formulations has been shown in clinical field trials in adults and children.6,8,9,21-23 No 181 
systematic vaccine-induced CD8+ T cell response was detected in PBMCs in our study, 182 
which was consistent with other studies that showed RTS,S/AS induces little or no 183 
detectable CD8+ T cell response.6,11,21,24,25 184 
The anti-CS humoral immune responses in this study tended to be lower than those 185 
observed following administration of three doses of RTS,S/AS01 or RTS,S/AS02 to 186 
malaria-experienced children in Africa13,14 but higher than those in African adults in a 187 
high malaria transmission area.12 Overall, in all studies including the present trial, 188 
RTS,S/AS formulations produced robust anti-CS antibody responses, with the AS01 189 
adjuvanted vaccine inducing higher responses than the AS02 adjuvanted formulation.12-190 
 9/27  
  
 
14 To further assess the quality of the antibody response, the relative avidity of anti-CS 191 
antibodies was measured in an ELISA procedure using the chaotropic agent, ammonium 192 
thiocyanate. The use of chaotropic agents is based on their ability to dissociate antibody-193 
antigen complexes of low avidity while complexes of high avidity remain intact.26 In the 194 
present study, the avidity of the anti-CS antibodies was in the same range for the three 195 
groups. This suggests that, while adjuvantation can have an impact on magnitude of the 196 
anti-CS response, it may have much less influence on the avidity of the elicited 197 
antibodies. 198 
Previous HBs-induced immune responses have been shown to enhance the CS-specific 199 
antibody response to adjuvanted RTS,S in children, most likely related to the covalently 200 
bound CS segment and HBs fusion protein in RTS,S.14 In this population of HBs-primed 201 
subjects, anti-HBs antibody titers increased dramatically after the first dose of study 202 
vaccine with no further increase upon subsequent doses. Various hypotheses could 203 
explain these observations: (i) more T and B cell epitopes are present in HBs than in the 204 
CS antigen, making HBs immunodominant over CS and leading to earlier maximum anti-205 
HBs antibody production than for CS; (ii) relatively lower doses of CS antigen are 206 
administered compared to HBs as there are fewer CS antigens than HBs antigens in 207 
RTS,S; (iii) competition at the T cell level, resulting in more and earlier T cell responses 208 
and B cell help for HBs-specific B cells than for CS; (iv) binding of RTS,S by anti-HBs 209 
antibodies followed by uptake and presentation of vaccine-derived peptides by HBs-210 
specific B cells, resulting in a rapid increase in HBs-specific antibodies and minimal 211 
priming of CS-specific T and B cells; and (v) higher levels of anti-HBs antibodies 212 
interfering with HBs boosting by binding and phagocytosis of vaccine particles. Most 213 
likely a combination of all or some of these mechanisms leads to the continuing rise of 214 
vaccine-induced anti-CS antibodies, while no further increase of anti-HBs responses is 215 
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observed after the second dose. It was also noted that adjuvanted RTS,S did not induce 216 
higher anti-hepatitis B booster responses than non-adjuvanted RTS,S.  217 
Reactogenicity was in general higher in the adjuvanted vaccine groups than in the non-218 
adjuvanted control group but was within acceptable limits and in line with previous 219 
experience of RTS,S/AS vaccines.4,27 Most grade 3 solicited symptoms were of short 220 
duration and grade 3 solicited general AEs were infrequent in all groups. Further 221 
interpretation of the safety results and immunogenicity analyses is limited by the small 222 
number of participants in each group. Another limitation of this study was the absence of 223 
a group of subjects without seroprotective anti-HBs antibody titers at baseline. 224 
In summary, adjuvanted RTS,S vaccines exhibited superior anti-CS humoral and CMI 225 
responses over non-adjuvanted RTS,S, with a tendency towards stronger immune 226 
responses induced by RTS,S/AS01 compared to RTS,S/AS02, which was in line with 227 
previous studies. The adjuvanted vaccines demonstrated an acceptable safety profile, 228 
although reactogenicity was generally higher with the adjuvanted vaccines than with 229 
non-adjuvanted RTS,S. These results, together with previously published studies, 230 
confirm the immunological basis for adjuvantation of RTS,S. 231 
Methods 232 
Study design and participants 233 
This phase II, randomized, double-blind (observer-blind) study was conducted at the 234 
Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, 235 
Belgium, between April and July in 2007 (ClinicalTrials.gov identifier: NCT00443131). 236 
Subjects were recruited primarily via advertisements posted at the University Hospital. 237 
Healthy malaria-naïve men or women of non-childbearing potential, aged 18 to 45 years 238 
at the time of first vaccination, who were seronegative for human immunodeficiency virus 239 
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(HIV 1 or 2), HBs, and hepatitis C virus antibodies, with seroprotective anti-HBs antibody 240 
titers (≥10 mIU/mL) at screening, were eligible for enrolment. All subjects had been 241 
immunized with the hepatitis B vaccine. Written informed consent was obtained from all 242 
participants before performing any study procedure.  243 
The study was reviewed and approved by the ethics review committee of the University 244 
of Ghent. The trial was undertaken according to the International Conference on 245 
Harmonization and Good Clinical Practice guidelines, and was monitored by 246 
GlaxoSmithKline Vaccines. The primary objective of the study was to demonstrate 247 
superiority of anti-CS antibody responses at 1 month post-dose 3 against RTS,S 248 
formulated with AS01 or AS02 compared to RTS,S reconstituted with saline. 249 
The participants were randomized (1:1:1), by a centralized randomization system on the 250 
internet administered by the investigator, to receive vaccination at months 0, 1, and 2 251 
with lyophilized RTS,S (50 µg) reconstituted with 500 µL of either AS01A, AS02B 252 
(referred to elsewhere in this paper as AS01 and AS02, respectively), or saline. The 253 
RTS,S vaccine has been described previously.3 The vaccines were administered 254 
intramuscularly to the deltoid muscle of the non-dominant arm and vaccine recipients 255 
were observed for at least 30 minutes following each vaccination.  256 
All laboratory assays were performed at the Center for Vaccinology, Ghent University 257 
and Hospital, or at the laboratories of GlaxoSmithKline Vaccines, Rixensart, Belgium, 258 
using standardized, validated procedures. 259 
Humoral immune response assessments 260 
Assessment of anti-CS and anti-HBs antibody titers was conducted on serum samples 261 
taken before dose 1 (at enrolment), one month after dose 1 (month 1), one month after 262 
dose 2 (month 2), and one month after dose 3 (month 3). Antibodies against CS were 263 
measured by evaluating IgG responses to the CS-repeat region, using a standard ELISA 264 
 12/27  
  
 
with R32LR as the capture antigen.28 An anti-CS antibody titer of 0.5 EU/mL or greater 265 
was considered to be positive. Anti-HBs antibodies were measured using an in-house 266 
ELISA; an antibody titer of 10 mIU/mL or greater was considered to be seroprotective.  267 
The avidity of anti-CS antibodies in sera was assessed at months 1, 2, and 3. The 268 
relative avidity of IgG antibodies was determined by ELISA with R32LR as coating 269 
antigen. The assay was an adaptation of the anti-CS assay28 and based on previous 270 
methodology on the dissociation of low avidity antibody-antigen complexes by the 271 
chaotropic agent, ammonium thiocyanate (NH4SCN).26 After sample addition, formed 272 
antigen-antibody complexes were treated with a 1M ammonium thiocyanate solution and 273 
remaining complexes were quantified. The result was compared to the concentration 274 
obtained when no treatment was applied and expressed as the avidity index, indicating 275 
the percentage of antibodies that remained bound to antigens. 276 
CMI response assessments 277 
Blood samples for CMI response analysis were collected at months 1, 2, and 3. CMI 278 
responses to the CS and HBs antigens were assessed using frozen PBMCs, which were 279 
isolated by standard Ficoll-Hypaque density gradient centrifugation and cryopreserved in 280 
liquid nitrogen within 12 hours of blood collection.  281 
CS-specific and HBs-specific CD4+/CD8+ T cells expressing the cytokines CD40L and/or 282 
IL-2 and/or TNF-α and/or IFN-γ were detected using ICS and flow cytometry, based on 283 
previously described methodology.29,30 Briefly, PBMCs were stimulated in vitro for 2 h 284 
with antigen or pools of peptides, which covered the entire sequence of the antigens, in 285 
the presence of anti-CD28 and anti-CD49d antibodies. The cells were then incubated 286 
overnight with brefeldin A to prevent cytokine excretion. The cells were stained for 287 
surface markers (CD4 and CD8), fixed and permeabilized, and stained with 288 
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fluorochrome-conjugated monoclonal antibodies to detect the immune markers by flow 289 
cytometry. 290 
Safety and reactogenicity evaluation 291 
Solicited local (injection site pain, redness, and swelling) and general (fatigue, fever, 292 
gastrointestinal symptoms [nausea, vomiting, diarrhea, abdominal pain], and headache) 293 
AEs were recorded by participants on diary cards during the 7-day follow-up after each 294 
vaccination. Information on unsolicited AEs were collected over 30 days after each 295 
vaccination. Serious AEs were reported throughout the study. Duration, causality, and 296 
outcome of AEs were recorded. All solicited local reactions were considered causally 297 
related to vaccination; the relationship of other AEs was classified as possible or not 298 
causally related. AE intensity was scored on a scale from 1 to 3. Grade 3 AEs were 299 
defined as preventing normal daily activity, apart from grade 3 solicited fever, which was 300 
defined as axillary temperature >39.0°C, and grade 3 solicited swelling or redness, 301 
defined as diameter >50 mm. Complete blood count, renal (creatinine) and hepatic 302 
functional tests (alanine aminotransferase and aspartate aminotransferase) were taken 303 
at screening and one month after the third vaccine dose. 304 
Statistical analyses 305 
A sample size of 10 evaluable subjects per group had 98% power to demonstrate 306 
superiority of RTS,S/AS01 over RTS,S/saline, assuming a log standard deviation not 307 
exceeding 0.7 and anti-CS GMTs of 5 EU/mL and 143 EU/mL for RTS,S/saline and 308 
RTS,S/AS01, respectively, and 91% power to demonstrate superiority of RTS,S/AS02 309 
over RTS,S/saline, assuming a log standard deviation not exceeding 0.7 and anti-CS 310 
GMTs of 5 EU/mL and 82 EU/mL for RTS,S/saline and RTS,S/AS02, respectively.  311 
Immunogenicity analysis was performed on the ATP cohort for immunogenicity, defined 312 
as those meeting all eligibility criteria, complying with the procedures defined in the 313 
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protocol, with no elimination criteria during the study, and for whom data concerning 314 
immunogenicity endpoint measures were available. Anti-CS and anti-HBs antibody 315 
GMTs were calculated with 95% CIs. The percentages of subjects with seropositive 316 
levels of anti-CS antibodies (≥0.5 EU/mL) and seroprotective levels of anti-HBs 317 
antibodies (≥10 mIU/mL) were determined. Superiority of RTS,S/AS01 or RTS,S/AS02 318 
over RTS,S/saline in terms of anti-CS antibody GMTs one month after the third vaccine 319 
dose was evaluated using a 2-sided T-test on the log10 transformed anti-CS titers 320 
(analysis of variance [ANOVA] model, pooled variance). The superiority condition was 321 
met if the p value was <0.025.  322 
The avidity of anti-CS antibodies was expressed as the avidity index, indicating the 323 
percentage of antibodies that remained bound to antigens after ammonium thiocyanate 324 
treatment. CMI responses were determined as the frequency of CS- and HBs-specific 325 
CD4+ and CD8+ T cells expressing at least two immune markers (CD40L, IL-2, TNF-α, 326 
and/or IFN-γ), presented as the percentage of T cells expressing at least two cytokines 327 
per million cells. 328 
The safety analysis was conducted on the total vaccinated cohort. Percentages of 329 
solicited or unsolicited AEs were calculated with exact 95% CIs. Clinically relevant 330 
abnormal laboratory values were determined according to predefined normal ranges.  331 
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Figure Legends 483 
Figure 1. CONSORT diagram of study flow in phase II randomized, double-blind study 484 
of humoral and cell-mediated immune responses against three doses of RTS,S malaria 485 
vaccine formulated with AS01 (RTS,S/AS01) or AS02 (RTS,S/AS02) compared to three 486 
doses of RTS,S reconstituted with saline (RTS,S/saline). 487 
Figure 2. Box plots of anti-CS antibody avidity index (percentage of antibodies that 488 
remained bound to antigen after ammonium thiocyanate treatment) in each group one 489 
month after each vaccine dose (ATP cohort for immunogenicity). Box indicates median 490 
and Q1 (median minus 25%) and Q3 (median plus 25%) values, whiskers indicate 491 
minimum and maximum values. M, month. 492 
Figure 3. Box plots for cytokine-positive T cell frequencies, defined as the percentage of 493 
CD4+ cells expressing at least two immune markers (CD40L, IL-2, TNF-α, and/or IFN-γ) 494 
per 106 CD4+ T cells, on stimulation with circumsporozoite (CS) and hepatitis B surface 495 
(HBs) antigens (ATP cohort for immunogenicity). Peripheral blood mononuclear cells 496 
were harvested, surface-labeled for CD4 and CD8 and then stained for intracellular 497 
detection of immune markers (see Methods). Cells were analyzed by flow cytometry. 498 
Box indicates median and Q1 (median minus 25%) and Q3 (median plus 25%) values, 499 
whiskers indicate minimum and maximum values. Pre, pre-vaccination; M, month. 500 
A. CS-specific CD4+ T cell responses 501 
B. HBs-specific CD4+ T cell responses 502 
Figure 4. Frequency of solicited local and general adverse events (overall per dose) 503 
occurring within 7 days of vaccination (total vaccinated cohort). 504 
Grade 3 defined as preventing normal daily activity, apart from grade 3 fever (>39.0°C) 505 
and grade 3 swelling or redness (diameter >50 mm) 506 
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A. Solicited local adverse events 507 
B. Solicited general adverse events  508 
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Table 1. Demographic characteristics (ATP cohort for immunogenicity).  509 
 RTS,S/AS01 
(N = 11) 
RTS,S/AS02 
(N = 11) 
RTS,S/Saline 
(N = 12) 
Mean age ± SD (years)  20.9 ± 2.3 20.7 ± 2.9 21.6 ± 2.3 
Age range (years) 18–25 18–28 18–26 
Gender (%), female/male 63.6/36.4 63.6/36.4 75.0/25.0 
SD, standard deviation; N, number of subjects 510 
  511 
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Table 2. Anti-CS and anti-HBs antibody GMTs by vaccine group one month after each vaccine dose (ATP cohort for immunogenicity).   
  Anti-CS GMT (EU/mL) Anti-HBs GMT (mIU/mL) 
Group Timing N Value (95% CI) Min Max Value (95% CI) Min Max 
RTS,S/AS01 PRE 11 0.3 (0.3–0.3) <0.5 <0.5 419 (65–2699) 29 52929 
 Month 1 11 43.9 (21.3–90.4) 3.4 259.5 356888 (170662–746324) 71649 1480452 
 Month 2 11 93.2 (58.3–149.2) 22.4 231.0 285434 (154715–526599) 60419 1384707 
 Month 3 11 160.3 (114.1–225.4) 78.6 363.0 204229 (105211–396436) 29148 1037696 
RTS,S/AS02 PRE 11 0.3 (0.3–0.3) <0.5 <0.5 124 (48–322) 14 1303 
 Month 1 11 30.2 (13.3–68.9) 4.4 189.0 536123 (224513–1280230) 37591 2802649 
 Month 2 11 58.8 (33.3–103.6) 18.4 263.4 255206 (93038–700038) 12536 863367 
 Month 3 11 77.4 (47.3–126.7) 22.2 202.2 216220 (101812–459188) 20510 570058 
RTS,S/Saline PRE 12 0.3 (0.3–0.3) <0.5 <0.5 404 (120–1358) 11 8844 
 Month 1 12 21.4 (8.2–55.6) 1.2 198.9 375772 (125743–1122963) 16770 3876614 
 Month 2 12 13.9 (5.9–32.8) 0.7 93.2 245373 (91656–656887) 11206 2436186 
 Month 3 12 12.2 (4.8–30.7) <0.5 65.8 187514 (87264–402930) 20092 1124210 
GMT, geometric mean antibody titer calculated on all subjects; N, number of subjects with available results; Min, minimum; Max, 
maximum; PRE, pre-vaccination; Month 1, one month after first vaccine dose; Month 2, one month after second vaccine dose; Month 3, 
one month after third vaccine dose. 
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Table 3. Anti-CS antibody geometric mean titer (GMT) ratios (first group over second 
group) at one month after the third vaccine dose (ATP cohort for immunogenicity).   
Group comparison GMT GMT ratio (95% CI) p valuea 
RTS,S/AS01 vs. RTS,S/Saline 160.35 vs. 12.19 13.15 (5.02–34.45) <0.0001 
RTS,S/AS02 vs. RTS,S/Saline 77.43 vs. 12.19 6.35 (2.30–17.50) 0.0011 
RTS,S/AS01 vs. RTS,S/AS02 160.35 vs. 77.43 2.07 (1.18 – 3.63) 0.0135 
a p value for differences in GMT (ANOVA model, pooled variance) 
vs., versus 
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Table 4. Frequency of unsolicited symptoms (reported in more than one subject in a 
single group) during the 30-day post-vaccination period (total vaccinated cohort).  
 Percentage of subjects (95% CI) 
Unsolicited symptom RTS,S/AS01 
(N = 12) 
RTS,S/AS02 
(N = 12) 
RTS,S/Saline 
(N = 12) 
Nausea 16.7 (2.1–48.4) 0.0 (0.0–26.5) 0.0 (0.0–26.5) 
Chills 16.7 (2.1–48.4) 0.0 (0.0–26.5) 0.0 (0.0–26.5) 
Injection site pruritus 16.7 (2.1–48.4) 8.3 (0.2–38.5) 0.0 (0.0–26.5) 
Nasopharyngitis 0.0 (0.0–26.5) 16.7 (2.1–48.4) 16.7 (2.1–48.4) 
Upper respiratory tract infection 0.0 (0.0–26.5) 16.7 (2.1–48.4) 0.0 (0.0–26.5) 
Arthralgia 16.7 (2.1–48.4) 0.0 (0.0–26.5) 0.0 (0.0–26.5) 
Myalgia 25.0 (5.5–57.2) 0.0 (0.0–26.5) 0.0 (0.0–26.5) 
Headache 16.7 (2.1–48.4) 33.3 (9.9–65.1) 16.7 (2.1–48.4) 
Pharyngolaryngeal pain 8.3 (0.2–38.5) 0.0 (0.0–26.5) 16.7 (2.1–48.4) 
Productive cough 16.7 (2.1–48.4) 0.0 (0.0–26.5) 0.0 (0.0–26.5) 
N, number of subjects 
 





